ClinicalTrials.gg

Program

ivosidenib

Also written as “Ivosidenib”, “Ivosidenib Oral Tablet” and “AG120”.

Its studies are mostly in Cholangiocarcinoma · Leukemia, Myeloid, Acute · Neoplasm Metastasis · Neoplasms, Unknown Primary, led by 6 companies.

Furthest: phase 3, since Jul 1, 201513 company-led studies, 5 open or runningNext primary completion: Oct 15, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Agios Pharmaceuticals50 open or runningphase 1since Jul 1, 2015Jul 1, 2015none ahead
Servier Bio-Innovation32 open or runningphase 3since Nov 7, 2023Apr 21, 2023Feb 1, 2028phase 3 · NCT06127407
Servier Affaires Médicales22 open or runningphase 3since May 17, 2023May 17, 2023Oct 15, 2027phase 3 · NCT05907057
CStone Pharmaceuticals10 open or runningphase 1since Oct 29, 2019Oct 29, 2019none ahead
Hoffmann-La Roche10 open or runningphase 2since Apr 5, 2018Apr 5, 2018none ahead
Servier11 open or runningphase 2since Sep 14, 2023Sep 14, 2023none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 1, 2015First study: phase 1 study in Healthy VolunteersNew to Agios PharmaceuticalsAgios Pharmaceuticals · NCT02489513 · 8 enrolled · United States
  2. Oct 15, 2015Phase 1 study in HealthyAgios Pharmaceuticals · NCT02579707 · 36 enrolled · United States
  3. Jun 9, 2016Phase 1 study in HealthyAgios Pharmaceuticals · NCT02831972 · 22 enrolled · United States
  4. Mar 2, 2017Phase 1 study in HealthyAgios Pharmaceuticals · NCT03071770 · 60 enrolled · United States
  5. Sep 8, 2017Phase 1 study in Hepatic ImpairmentAgios Pharmaceuticals · NCT03282513 · 33 enrolled · United States
  6. Apr 5, 2018Hoffmann-La Roche's first study: phase 2 study in Neoplasms, Unknown PrimaryNew to Hoffmann-La RocheHoffmann-La Roche · NCT03498521 · 529 enrolled · Australia, Austria, Brazil and more
  7. Oct 29, 2019CStone Pharmaceuticals's first study: phase 1 study in RecurrenceNew to CStone PharmaceuticalsCStone Pharmaceuticals · NCT04176393 · 30 enrolled · China
  8. Apr 21, 2023Servier Bio-Innovation's first study: phase 2 study in IDH1-mutant CholangiocarcinomaNew to Servier Bio-InnovationServier Bio-Innovation · NCT05921760 · 7 enrolled · United States, United Kingdom
  9. May 17, 2023Servier Affaires Médicales's first study: phase 3 study in CholangiocarcinomaNew to Servier Affaires MédicalesServier Affaires Médicales · NCT05876754 · 299 enrolled · Armenia, Australia, Austria and more
  10. Jun 8, 2023Phase 3 study in Leukemia, Myeloid, AcuteServier Affaires Médicales · NCT05907057 · 245 planned · Austria, France, Italy and more
  11. Sep 14, 2023Servier's first study: phase 2 study in Cholangiocarcinoma Non-resectableNew to ServierServier · NCT06081829 · 12 enrolled · Japan
  12. Nov 7, 2023Phase 3 study in Neoplasm MetastasisServier Bio-Innovation · NCT06127407 · 156 planned · United States, Australia, Belgium and more
  13. May 27, 2025Phase 1 study in IDH1-Mutated MalignanciesServier Bio-Innovation · NCT07006688 · 30 planned · United States, Australia, Brazil and more

Ahead

  1. Oct 15, 2027Primary completion: phase 3 study in Leukemia, Myeloid, AcuteServier Affaires Médicales · NCT05907057
  2. Dec 1, 2027Primary completion: phase 3 study in CholangiocarcinomaServier Affaires Médicales · NCT05876754
  3. Feb 1, 2028Primary completion: phase 3 study in Neoplasm MetastasisServier Bio-Innovation · NCT06127407
  4. Jul 31, 2028Primary completion: phase 1 study in IDH1-Mutated MalignanciesServier Bio-Innovation · NCT07006688

TargetBeta

IDH1 →read by rule
“An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), ”NCIt, by rule
“Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor”ChEMBL 37, by rule

Other programs on IDH1

ProgramCompanyFurthest phaseStudies
olutasidenibruleRigel Pharmaceuticalsphase 45
vorasidenibruleAgios Pharmaceuticalsphase 312
ranosidenibruleHUTCHMEDphase 37
safusidenibruleNuvation Biophase 36
IDH1 Inhibitor TQB3454Sino Biopharmaceuticalphase 35

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07006688IDH1-Mutated Malignancies · United States, Australia, Brazil and more1RecruitingServier Bio-InnovationJul 31, 202830
NCT06127407Neoplasm Metastasis · United States, Australia, Belgium and more3RecruitingServier Bio-InnovationFeb 1, 2028156
NCT06081829Cholangiocarcinoma Non-resectable · Japan2Active, not recruitingServierOct 1, 202412
NCT05907057Leukemia, Myeloid, Acute · Austria, France, Italy and more3RecruitingServier Affaires MédicalesOct 15, 2027245
NCT05876754Cholangiocarcinoma · Armenia, Australia, Austria and more3Active, not recruitingServier Affaires MédicalesDec 1, 2027299
NCT05921760IDH1-mutant Cholangiocarcinoma · United States, United Kingdom2TerminatedServier Bio-InnovationNov 21, 20247
NCT04176393Recurrence · China1CompletedCStone PharmaceuticalsFeb 18, 202130
NCT03498521Neoplasms, Unknown Primary · Australia, Austria, Brazil and more2CompletedHoffmann-La RocheFeb 14, 2023529
NCT03282513Hepatic Impairment · United States1CompletedAgios PharmaceuticalsMar 31, 201833
NCT03071770Healthy · United States1CompletedAgios PharmaceuticalsMay 9, 201760
NCT02831972Healthy · United States1CompletedAgios PharmaceuticalsSep 201622
NCT02579707Healthy · United States1CompletedAgios PharmaceuticalsFeb 201636
NCT02489513Healthy Volunteers · United States1CompletedAgios PharmaceuticalsSep 20158

How it is read

Names in the registry

  • “Ivosidenib”, 3 entries
  • “Ivosidenib Oral Tablet”, 2 entries
  • “AG120”, 2 entries
  • “Ivosidenib 500mg”, 1 entry
  • “Ivosidenib 500mg Oral Tablet”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.